13th July 2022 | Pharma Updates

HC declines to restrict Sun Pharmaceuticals from using the term "Respules"

Sun Pharmaceuticals Industries Limited in Nandanam has been allowed to continue using the term “Respules” in its commercial operations without being prohibited from doing so by the Madras High Court.

SII launch an indigenously manufactured vaccine to treat cervical cancer

Serum Institute of India (SII) received market authorization from the Drugs Controller General of India (DCGI) to produce India’s first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer.

Indian pharma to provide cell-based cancer therapy at one-tenth the cost of the US

In India, an estimated 26.7 million people will have cancer by 2021, and that number is likely to rise to 29.8 million by 2025. This medication for cancer patients may soon be made available by Indian pharmaceutical startups and enterprises.

DoP adjusts SPI scheme guidelines following discussions with the industry

The Department of Pharmaceuticals (DoP) has changed the rules for the Strengthening of Pharmaceutical Industry (SPI) programme to provide grantees of several of its programmes an extra 30 months to finish upgrading their technology after the first loan disbursement.

India's first Single Screen EMR introduced by MyHealthcare

On Tuesday, MyHealthcare announced the rollout of India’s first single-screen EMR, a technology that enables medical professionals to enter all patient encounter-related medical records on a single screen.

TDS Exemption requested by Medical Device Manufacturers for free medical samples

As per regulations, free medical samples delivered to doctors, reimbursement of out of pocket expenses made by healthcare practitioners, and expenditure related to dealer or customer business conferences would be considered benefits and hence subject to TDS deduction.

Faster treatment access supported by USFDA guidance on patient-focused drug development

The latest US FDA proposed regulations on patient-focused drug development: choosing, creating, or altering fit-for-purpose clinical outcome assessments are highly relevant to the pharmaceutical sector.